Publicaciones (30) Publicaciones de ANNA MERLO

2023

  1. Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera

    Hematology (United Kingdom), Vol. 28, Núm. 1

2022

  1. Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide

    British Journal of Cancer

2020

  1. Logistics of an advanced therapy medicinal product during COVID-19 pandemic in Italy: successful delivery of mesenchymal stromal cells in dry ice

    Journal of Translational Medicine, Vol. 18, Núm. 1

2017

  1. A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

    OncoImmunology, Vol. 6, Núm. 4

  2. Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells

    Frontiers in Immunology, Vol. 8, Núm. FEB

  3. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate

    Oncotarget, Vol. 8, Núm. 4, pp. 6700-6717

2016

  1. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer

    Journal of Controlled Release, Vol. 236, pp. 79-89

  2. Reverse immunoediting: When immunity is edited by antigen

    Immunology Letters, Vol. 175, pp. 16-20

2015

  1. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer

    Oncoscience, Vol. 2, Núm. 4, pp. 373-381

  2. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy

    Head and Neck, Vol. 37, Núm. 8, pp. 1150-1162

2014

  1. Functional avidity-driven activation-induced cell death shapes CTL immunodominance

    Journal of Immunology, Vol. 193, Núm. 9, pp. 4704-4711

  2. PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models

    PLoS ONE, Vol. 9, Núm. 10

  3. Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs

    PLoS ONE, Vol. 9, Núm. 11

2013

  1. Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22.2 for migratory capacity in head and neck squamous cell carcinomas

    BMC Cancer, Vol. 13

  2. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1αmiR-210 signaling pathway

    Journal of Clinical Endocrinology and Metabolism, Vol. 98, Núm. 10

  3. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST)

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for epstein-barr-virus-driven disorders

    Clinical and Developmental Immunology, Vol. 2012

  2. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas

    Clinical Cancer Research, Vol. 18, Núm. 15, pp. 4080-4091

  3. Identification of a signaling Axis HIF-1α/MicroRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas

    Journal of Clinical Endocrinology and Metabolism, Vol. 97, Núm. 11

  4. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma

    Clinical Cancer Research, Vol. 18, Núm. 10, pp. 2828-2837